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immunoglobulin heavy gene (IgH) rearrangement as
a diagnostic tool in B lymphomas.
From 1996 to 1999 we analyzed 84 patients (48
male, 36 female, median age 62 years) with low grade
B-NHL. According to the R.E.A.L. classification, 44
patients had follicular lymphoma (FL), 21 lymphocyt-
ic lymphoma (LL), 11 mantle-cell lymphoma (MCL),
5 hairy-cell leukemia (HCL) and 3 marginal zone B-cell
lymphoma. The molecular analysis we used to evalu-
ate MRD was based on the determination of IgH
rearrangement through amplification by PCR. We
chose the combination of FR2 and FR3A semi-nested
methods, that, as has been demonstrated, reveals 85%
of monoclonality. PCR analysis was performed on tis-
sue, peripheral blood (PB) and bone marrow (BM) at
diagnosis, and on only PB and BM after therapy and
during follow-up. A patient is considered PCR positive
when one of the samples results positive.
Results. Overall IgH+ rate was 83% (73% in FL and
93% in non-FL). We analyzed 71 patients at diagno-
sis: IgH rearrangement was identified in tissue, PB
and BM samples in 87%, 60% and 72% of the cases,
respectively. In FL (39 patients) IgH+ rates in tissue,
PB and BM samples were 82%, 41% and 62% respec-
tively, whereas in non-FL (32 patients) they were 95%,
83% and 90%, respectively. Twenty-seven patients
received conventional chemotherapy; IgH+ rates were
85% at diagnosis and 44% after therapy. Ten patients
(6 FL, 3 LL and 1 MCL) underwent treatment with
high-doses of cyclophosphamide followed by ABMT.
IgH+ rate was 90% at diagnosis and 55% after ABMT. 
In 1998 we started to search for Bcl-2 translocation
as a molecular marker specific for FL. Twenty patients
with FL were studied at diagnosis and 60% of them
resulted Bcl-2+, whereas 12 patients were treated and
25% of them resulted Bcl-2+ after treatment.
Conclusions. Our results demonstrate that the IgH
rearrangement is an extremely sensitive method in
monitoring MRD in low grade B-NHL. In particular, it
is more useful at diagnosis for non-FL, whereas it is
advisable to use both IgH rearrangement and Bcl-2
translocation for FL. At diagnosis, the most significant
results by using PCR analysis are obtained on tissue;
however, it was important for us to perform it both on
PB and BM because in some cases (11) we obtained
PB+ and BM– after therapy. Conventional therapy and
ABMT do not induce a significantly high molecular
response. When a follow-up evaluation is performed
there is a good correlation between molecular results
and clinical outcome. It is then possible to associate
the presence of monoclonality after ABMT with an
increase of incidence of relapse. In conclusion, the
detection of MRD by PCR of IgH rearrangement could
have a prognostic value and a clinical significance, and
most of all can be useful to assess the role of ABMT
according to the results obtained.  
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Introduction. The functional activity of polymor-
phonuclear neutrophils (PMNs) in patients with B-
cell chronic lymphocyte leukemia (B-CLL) is still con-
troversial due to the heterogeneity of the disease and
individual variability, although normal absolute num-
bers of PMNs have been described. We have recent-
ly shown1 a significant (p<0.001) decrease in the abil-
ity to release reactive oxygen intermediates in the
PMA-induced nitroblue tetrazolium test (NBT) by
PMNs of B-CLL patients (37.9±19.0%, range 12-
83%) compared with normal controls (81.5±12.7%,
range 59-94%). Both, the number of NBT+ PMNs and
the intensity of the formation of formazan crystals
were decreased.
Methods. The detection of immature PMNs was
measured by the activity of leukocyte alkaline phos-
phatase (LAP) using a Sigma LAP kit in 10 untreated
Rai staged patients (age range 48-77) and 10 age-
matched controls. PMN were analyzed morphologi-
cally to determine banding. A possible overall
decrease in enzymes, related to oxygen-dependent
bactericidal function was evaluated by the expression
of myeloperoxidase (MPO) in PMNs using a cyto-
chemical assay (Sigma). The ability of PMNs to
attach and engulf opsonized target cells was also test-
ed. For this purpose, Staphylococcus aureus were
opsonized with specific rabbit polyclonal IgG anti-
bodies (Molecular Probes) and added to PMNs iso-
lated on double Ficoll gradients. Cells were incubat-
ed for 30 minutes at 37°C, washed and stained with
Giemsa. The numbers of PMNs with internalized
and/or attached opsonized bacteria were evaluated
per 200 PMNs.
Results: The intracellular expression of LAP by blood
PMNs in B-CLL patients (67.7±13.2%, range 52-81%)
did not differ from that in healthy controls
(71.7±15.2, range 50-85%), excluding immaturity of
the PMNs as a factor. Morphologic analysis con-
firmed that there were very few band-type immature
PMNs in the blood of B-CLL patients. The expression
of MPO by B-CLL PMNs (94.3±1.5%) was no differ-
ent from that of normal controls (92.7±1.9%), sug-
gesting that the oxygen-dependent peroxidase system
was not impaired. Although attachment of the
opsonized particles was similar to that in controls,
there was, nevertheless, a significant decrease in inter-
nalization by B-CLL PMNs (Table 1).
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Table 1. Internalization of opsonized S.aureus. 
PMN with or without S. aureus, %
Source of cells Attached Attached and Internalized None
only internalized only
B-CLL patients 36.0±11.1 5.6±5.9 14.3±10.9 42.3±25.3
Controls 37.5±4.0 17.4±8.6 40.2±5.9 4.9±0.8
P > 0.05 > 0.05 < 0.001 < 0.01
*Mann-Whitney test (the data represent mean ± standard deviation).
Conclusions. Our data are consistent with a reduced
phagocytic function of PMNs of B-CLL patients
which might contribute to the increased susceptibil-
ity to infection in this disease.
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FLUDARABINE IN COMBINATION THERAPY IS AN EFFEC-
TIVE TREATMENT FOR RELAPSED OR REFRACTORY LOW-
GRADE NON-HODGKIN’S LYMPHOMA: A MULTICENTER
EXPERIENCE
Congiu A, Nati S, Gallamini A, Pierluigi D, Marino G, Santini G
Department of Hematology, San Martino Hospital, Genoa, Italy
The aim of our study was evaluate the efficacy and
safety of fludarabine in combination with cyclophos-
phamide or with mitoxantrone and cyclophos-
phamide in patients with recurrent low-grade lym-
phoma (LGL). Fifty-three patients entered the study.
Twenty-two patients received cyclophosphamide
(300 mg/m2 i.v. days 1-3) followed by fludarabine
(25 mg/m2) in 30 min. infusion days 1-3, every 28
days for a maximum of 6 cycles; 31 patients also
received mitoxantrone (10 mg/m2 given over 15 min.
infusion on day 1. All patients received antibiotic pro-
phylaxis and growth factors (G-CSF) if grade III gran-
ulocytopenia (WHO) occurred. All patients had
failed a median number of 2 (range 1 to 5) previous
chemotherapy regimens containing either doxoru-
bicin or mitoxantrone. Mean age was 56 years (35-
75). According to the REAL classification, 12 patients
had small B lymphocytic, 34 patients follicular, 5
mantle cell and 2 marginal zone NHL. The overall
response rate in all patients was 88% (58% with CR).
In FLU/CY it was 95% compared with 84% in
FLU/CY/MITO. After 3 courses, 58% of overall CR
was achieved with FLU/CY treatment and 90% with
FLU/CY/MITO (p=0.02). There was no statistical dif-
ference in response rate between the treatments.
Median time to disease progression was 6 months.
One patients died with fever of unknown origin 3
months after 6 courses of FLU/CY while in CR. Both
therapies were well tolerated. Grade 3 or 4 neu-
tropenia was observed in 39 courses, and had a sim-
ilar distribution between the two groups. Non-hema-
tologic toxicity was very mild in both arms and rep-
resented by grade 1 nausea and vomiting in two
patients. No other toxicity was observed. Both com-
bination therapies were seen to be effective in treat-
ing recurrent low-grade lymphoma in patients previ-
ously treated with regimens containing doxorubicin
or mitoxantrone, but fewer patients relapsed with
FLU/CY/MITO and the fast activity of this treatment
suggests it to be more useful. Overall results were
similar, consequently it is difficult to draw sure indi-
cation about the opportuness of choosing one or the
other treatment. 
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Background. In a phase II study the P-VABEC regimen
resulted to be an active and well tolerated therapy for
elderly patients with diffuse large cell lymphomas
(Martelli,  J Clin Oncol 11:2363; 1993). Further studies
reported on a larger series of patients treated with P-
VABEC demonstrated that in spite of a high rate of
complete response (CR) the event-free survival (EFS)
rapidly decreased with a high incidence of early
relapse. Moreover a significantly worse EFS was
shown for patients with a high-risk IPI score com-
pared to those with a low-risk IPI  (Martelli, Ann Oncol
1999; 10 suppl. 3, 55). A phase II study reported by
Caracciolo (Leuk Lymphoma 1997; 24:335) demon-
strated an improvement of survival after cisplatin,
idarubicin, prednisone (CIP) as consolidation chemo-
therapy in patients responsive to P-VABEC.
Purpose. To evaluate the activity and toxicity of CIP
consolidation therapy after P-VABEC versus the stan-
dard P-VABEC regimen in a prospective, randomized,
phase III study.
Patients and methods. From October 1995 to April
2000 we enrolled 198 previously untreated patients
with diffuse large cell lymphomas (according to the
REAL classification), median age 70 years (range 60-
85), stage II-IV. All elegible patients were random-
ized at diagnosis to receive P-VABEC (group 1) or P-
VABEC-CIP (group 2).The P-VABEC is an 8 weekly
regimen delivered on a out-patient basis: doxorubicin
30 mg/m2, etoposide 100 mg/m2, cyclophosphamide
350 mg/m2 given in weeks 1, 3, 5, 7 and vincristine
1.4 mg/m2, bleomycin 15 mg/td in weeks 2, 4, 6, 8.
A daily prednisone dose of 50 mg is given orally dur-
ing the entire regimen.  The CIP consolidation thera-
py started 21 days after the last P-VABEC cycle, in
patients who obtained a response (complete or par-
tial). Patients with minimal response or progressive
disease after P-VABEC were excluded from consoli-
dation therapy. The CIP schedule consisted of cis-
